TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05809908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricaprilin
Description: Each dose of IMP will be administered orally 30 minutes after completing a meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each dose of IMP will be administered orally 30 minutes after completing a meal.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of safflower oil; 80 ml total daily dose of placebo, over the course of 3 weeks.
Study: NCT06585111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: In the first motivational interview, the HAPA Model Prenatal Motivation Interview Questionnaire, the first part of the Personal Information Form, the Prenatal Breastfeeding Self-Efficacy Scale, and the Breastfeeding Intention Scale for Pregnant Women Expecting Twins were applied. A brochure on breastfeeding twin babies prepared by the researcher was distributed to women. In the second interview, the HAPA Model Postpartum Motivation Interview Scale, the second part of which was the Personal Information Form, Breastfeeding Follow-up Form, Breastfeeding Motivation Scale and Postpartum Breastfeeding Self-Efficacy Scale were applied. In the third meeting, the Breastfeeding Follow-up Form was applied. Breastfeeding Motivation Scale, Postpartum Breastfeeding Self-Efficacy Scale and Breastfeeding Follow-up Form were applied in the fourth and fifth interviews, and Breastfeeding Follow-up Form was applied in the sixth interview.
Study: NCT04659044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06577259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986435
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986435
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986435
Description: Specified dose on specified days
Study: NCT05518812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboprost Tromethamine
Description: During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.
Study: NCT04258566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Molecular Imaging
Description: Tracks and localizes intrahepatic lesions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Fluorescent dye used for visualization of cells and tissue
Study: NCT04966013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RD-X19
Description: Investigational device that uses safe electromagnetic energy to target the oropharynx.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RD-X19
Description: Investigational device that uses safe electromagnetic energy to target the oropharynx.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro..
Study: NCT05819658

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GV1001 Placebo
Description: 0.9% normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 0.56mg
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 1.12mg
Description: Lyophilized peptide from hTERT
Study: NCT05794321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous TXA
Description: Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.
Study: NCT06365697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ton-bridge carotid stent
Description: carotid artery stenting with Ton-bridge carotid stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WALLSTENT carotid stent
Description: carotid artery stenting with WALLSTENT carotid stent
Study: NCT05233189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOOC
Description: Registrants will be offered a personalized e-education consisting of 3 to 11 modules adapted to the treatment received in childhood by each in the form of a MOOC entitled Cancer in childhood, living well after over a total duration of about 3 to 7 weeks of training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Patients will be followed up until 18 months only
Study: NCT05331638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Genius App
Description: Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: US Prevention Taskforce App
Description: Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
Study: NCT04683042

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) with PT
Description: Use of TENS units along with routine PT therapy

Intervention type: OTHER
Group type: OTHER
Intervention: PT only
Description: Routine PT therapy only
Study: NCT05071287

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mHealth + low-fat diet
Description: A restricted total calorie and reduced total fat consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth + low-carb/ketogenic diet
Description: A low-carb/ketogenic diet
Study: NCT06494267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental (Video-Assisted Self-Assessment on Nasogastric Tube Insertion)
Description: Students in the experimental group will be videotaped while practicing and students will make self-evaluations.
Study: NCT04287218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TG-iConquerFear
Description: The theoretical frame of iConquerFear is based on the Common-Sense Model of illness, the Self-Regulatory Executive Function model and Relational Frame Theory. The intervention includes elements of attention training, increasing metacognitive awareness, acceptance \& mindfulness, promotion of appropriate screening behavior, and values-based goal setting. The electronic platform comprises 5 modules containing educational text, interactive exercises, short videos featuring doctors, therapists and patients' perspectives.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aTAU
Description: Active control group
Study: NCT06342037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: 600mg every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: 600mg every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: 600mg every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg, maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg, maximum of 4 cycles
Study: NCT05271643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CF-CBT-A is an 10-session program for adolescents with cystic fibrosis introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained mental health clinician on their CF team who will guide them through learning and practicing coping skills. Parents/guardians involvement will be encouraged. A parent/guardian will attend the baseline and final session, have the opportunity for a mid-program check-in, and receive a workbook of psychoeducational material that parallels the adolescent workbook, featuring tips for supporting their teens, and weekly e-mail communication.
Study: NCT04086927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unna Boot
Description: The unna boot is a zinc coated compression dressing
Study: NCT05468099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash and Povidone-Iodine
Description: Chlorhexidine mouth rinse which participants use for 20 seconds before procedure. Moreover, Povidone-Iodine nasal swabs are used to disinfect nostrils

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High volume evacuator
Description: High volume evacuator held by assistant to capture dental spray

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High volume evactuator and saliva ejector
Description: High volume evacuator and saliva ejector held by assistant to capture dental spray

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local Exhaust System
Description: Local exhaust system hovers above patient head to capture dental spray
Study: NCT05816252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: intravenous (IV) infusion (Q2W or Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: intravenous (IV) infusion (Q2W or Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: intravenous (IV) infusion (Q2W or Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: intravenous (IV) infusion (Q2W or Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: intravenous (IV) infusion (Q2W or Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: intravenous (IV) infusion (Q2W or Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: intravenous (IV) infusion (Q2W or Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: intravenous (IV) infusion (Q2W or Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous (IV) infusion (400mg, Q6W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous (IV) infusion (400mg, Q6W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous (IV) infusion (400mg, Q6W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous (IV) infusion (AUC5, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous (IV) infusion (AUC5, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous (IV) infusion (AUC5, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous (IV) infusion (AUC5, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg, QD
Study: NCT05083923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate
Description: Administered as specified in the treatment arm
Study: NCT05643495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-864
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-864
Description: Tablets for oral administration.
Study: NCT06038864

Intervention type: DIAGNOSTIC_TEST
Intervention: 2 clinical evaluations with 1 month in between
Description: Patients will be evaluated twice with all evaluation methods selected by the international expert group (cfr. aim 1) showing sufficient reliability and feasibility in the patient group with LLL from aim 1

Intervention type: DIAGNOSTIC_TEST
Intervention: 2 clinical evaluations with 1 month in between
Description: Patients will be evaluated twice with all evaluation methods selected by the international expert group (cfr. aim 1) showing sufficient reliability and feasibility in the patient group with LLL from aim 1
Study: NCT06589869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EM Chair
Description: Patients who randomised to intervention group (Arm A) will receive HIFEM assisted (BTL EMsella) pelvic floor muscle training for total 6 sessions (2 session per week, 30 minutes per session with modulated intensity) plus standard of care. The intervention will be started within 2 weeks after Foley Catheter removed. Patients will attend follow up for training and at 1, 3 and 6 month post-operatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care. Perioperative education for information related to prostatectomy and pelvic floor exercise training. Patient were advice to perform pelvic floor exercise at least 30 times per day
Study: NCT06588556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICUconnect
Description: ICUconnect is essentially digital infrastructure for facilitating consistent person-centered communication. It is a web app platform that works on any digital device (smartphone, computer, tablet) and uses a series of automated and timed text messages and emails to direct family members and clinicians to perform timeline-driven tasks (e.g., surveys, content review, coaching features, family meetings) across the 7- to 10-day intervention period.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Control family participants will receive standard ICU care that includes the study team's suggestion to clinicians to conduct regular family meetings. While control participants will also report needs, all family meetings that occur, and other outcomes via texted or emailed links to surveys within the app platform, control group needs will not be visible to clinicians and ICUconnect content will not be visible to family members. However, basic study information and staff contacts will be available on a control group-specific website accessible via links sent by the platform at the time of each data collection.
Study: NCT06596512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARTICS using a single ICS add on
Description: Participants randomized to PARTICS who use a nebulizer less than once a week are instructed to use the study prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARTICS using a single ICS add on
Description: Participants randomized to PARTICS who use a nebulizer less than once a week are instructed to use the study prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MART
Description: Participants are instructed to use prescribed study ICS/LABA for maintenance and as needed for rescue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MART
Description: Participants are instructed to use prescribed study ICS/LABA for maintenance and as needed for rescue.
Study: NCT06595186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: JK-1201I will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: JK-1201I will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Temozolomide will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Temozolomide will be administered.
Study: NCT06602336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Lactate Monitoring Device
Description: Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device.
Study: NCT06600854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BoneTape
Description: BoneTape is a craniofacial fracture repair device intended for use in the fixation of non-load-bearing bones of the craniofacial and midfacial skeleton. It can be used in skeletally mature individuals but is not intended for use in the mandible and/or full load bearing procedures. It is composed of: 1) BoneTape implant (device), and 2) BoneTape applicator (applicator).
Study: NCT06587438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinocare iCan I3 CGM
Description: Real-time Continuous glucose monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinocare jinzhi+Blood glucose meter
Description: Self-monitoring of blood glucose
Study: NCT06594887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpaceOAR Vue
Description: Peri-rectal hydrogel spacer consists of a layer of polyethylene-glycol gel (SpaceOAR vue) in order to outdistance the prostate from anterior rectal wall

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioProtect Balloon Implant System
Description: The balloon spacer is a biodegradable balloon made of poly (L-Lactide-co-caprolactone) which is a co-polymer of Poly Lactide acid and epsilon Caprolactone (BioProtect Balloon Implant System, BioProtect Ltd) inflated with saline, providing around 18 mm space height , and can be deflated and repositioned if needed, both laterally and along the distal /proximal planes, for optimal uniformity of spacing.
Study: NCT05464680

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blood sample and bronchoalveolar lavage
Description: These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample and bronchoalveolar lavage
Description: These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60.